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Abstract 
The neurotrophin growth/differentiation factor 5 (GDF5) is studied as a potential therapeutic 
agent for Parkinson’s disease as it is believed to play a role in the development and 
maintenance of the nigrostriatal system. Progress in understanding the effects of GDF5 on 
dopaminergic neurones has been hindered by the use of mixed cell populations derived from 
primary cultures or in vivo experiments, making it difficult to differentiate between direct and 
indirect effects of GDF5 treatment on neurones. In an attempt to establish a useful model to 
study the direct neuronal influence of GDF5, we have characterised the effects of GDF5 on a 
human neuronal cell line, SH-SY5Y. Our results show that GDF5 has the capability to 
promote neuronal but not dopaminergic differentiation. We also show that it promotes 
neuronal survival in vitro following a 6-hydroxydopamine insult. Our results show that 
application of GDF5 to SH-SY5Y cultures induces the SMAD pathway which could 
potentially be implicated in the intracellular transmission of GDF5’s neurotrophic effects. 
Overall, our study shows that the SH-SY5Y neuroblastoma cell line provides an excellent 
neuronal model to study the neurotrophic effects of GDF5. 
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Introduction 
Parkinson’s disease (PD) is a common neurodegenerative disorder characterised by the 
selective and progressive loss of the dopaminergic neurones of the substantia nigra pars 
compacta (SNpc) and the presence of intraneuronal proteinaceous inclusions known as Lewy 
bodies within the surviving neurones (Braak et al. 2003; Cookson 2005). Clinical symptoms 
usually appear when ~50% of dopaminergic neurones in the SNpc are lost, leading to a 
depletion of dopamine in the corpus striatum. Most of the available therapies aim to reduce 
the symptoms of the disease but cannot stop the progressive neurodegeneration or promote 
survival of the remaining neurones. Neuroprotective therapy could offer ways of preserving 
these neurones and, when administered with symptomatic treatments, could improve the 
long-term outcome for patients. Several compounds are being investigated as potential 
neuroprotectants (Toulouse and Sullivan 2008). 
 
A group of dimeric proteins known for their neurotrophic properties has recently attracted 
much attention. Glial cell line-derived neurotrophic factor (GDNF) and neurturin (NRTN) 
have produced potent neurotrophic effects on dopaminergic neurones in vivo and in vitro. 
They have been shown to protect cultured dopaminergic neurones from a variety of insults 
(Akerud et al. 1999; Horger et al. 1998; Lin et al. 1993) and prevent 6-hydroxydopamine- (6-
OHDA) and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine- (MPTP) induced nigrostriatal 
damage in animal models (Gasmi et al. 2007a; Gasmi et al. 2007b; Herzog et al. 2007; 
Kordower et al. 2006). Intraputamenal injections of GDNF were initially successful in open-
label trials but this was not replicated in a randomized double-blind trial (Gill et al. 2003; 
Patel et al. 2005; Slevin et al. 2005). Differences in the selection of patients, catheter design 
and drug dosage may explain the discrepancy. Intraputamenal injection of an adeno-
associated virus type 2 (AAV2)-based NRTN expression vector initially proved to be very 
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efficient. Results from an open-label trial showed that 6 months after receiving the injection, 
patients showed a 25% reduction in their “off” medication UPDRS score, a 50% reduction in 
their “off” time and an increase in periods without dyskinesia (Marks et al. 2006). However, 
an 18 month assessment of a double-blind trial of intraputamenal AAV2-NTN showed only 
minor clinical improvements (Bartus 2009).  
 
Growth/differentiation factor 5 (GDF5) is a member of the TGFB superfamily, that is related 
to GDNF and NRTN. In its active state, GDF5 forms a dimer that has binding affinity for 
various cell surface receptors; the bone morphogenetic proteins (BMP) receptors and the 
orphan receptor ROR2. Binding of GDF5 to BMPR1a or BMPR1b recruits BMPR2 to form a 
serine/threonine kinase receptor dimer that activates the SMAD family of nuclear 
transcription factors, SMAD 1/5/8 and the co-factor SMAD4 (ten Dijke et al. 2000). GDF5 
has higher affinity for BMPR1b than BMPR1a (Nishitoh et al. 1996). Alternatively, the 
BMPR1b receptor can form a heterodimer with the ROR2 tyrosine kinase receptor in the 
presence or absence of GDF5 (Sammar et al. 2004). It has been shown that formation of this 
receptor complex inhibits SMAD signalling, most likely by sequestering BMPR1b and 
therefore providing a negative modulation loop (Sammar et al. 2009; Sammar et al. 2004). 
 
GDF5 is expressed in many regions of the brain, including the midbrain. It is expressed in the 
ventral mesencephalon (VM) from embryonic day (E) 12, peaking at E14, the time of peak 
dopaminergic neurogenesis (Clayton and Sullivan 2007; O'Keeffe et al. 2004b). In vitro 
studies have shown that GDF5 treatment of VM cultures promotes the survival and the 
morphological differentiation of dopaminergic neurones and protects cultured dopaminergic 
neurones from MPP+-induced cell death, suggesting that it may play a role in the 
development and maintenance of the nigrostriatal system (Krieglstein et al. 1995; O'Keeffe et 
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al. 2004a). In vivo studies using the 6-OHDA-lesioned rat model of PD have shown that 
intracerebral injection of GDF5 protects the nigrostriatal pathway (Hurley et al. 2004; 
Sullivan et al. 1997; Sullivan et al. 1999). Furthermore, GDF5 was found to be as effective as 
GDNF in promoting the survival and functional integration of embryonic VM grafts in 6-
OHDA-lesioned rats (Sullivan et al. 1998).  
 
It remains unclear whether GDF5’s neurotrophic effects are mediated by direct actions on the 
dopaminergic neurones or are the results of secondary signalling from the surrounding glia. 
Most experiments conducted so far involved primary cultures or the use of animal models 
which do not allow separation of these effects. A paper by Wood et al. where primary 
cultures were treated with 5-FdU to prevent the growth of glial cell suggested that at least 
part of the dopaminergic neurotrophic effects of GDF5 may be through direct action on 
neurones (Wood et al. 2005); but otherwise, very little information is available. The 
experiments presented here aimed to assess the direct effects of GDF5 in a neuronal model, 
the SH-SY5Y cell line. Our results show that some of the neurotrophic effects of GDF5 can 
be reproduced in this model, mainly its capacity to promote neuronal survival and 
differentiation and that the SH-SY5Y is an ideal system for studying the effects of GDF5 on 
these parameters.  
 
Materials and Methods 
 
Cell culture 
 
SH-SY5Y cells were maintained in Dulbecco’s Modified Eagle’s Medium:Ham’s F12 
mixture (1:1, DMEM:F12, Sigma-Aldrich) supplemented with 10% fetal calf serum (Sigma-
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Aldrich), 100 mM L-glutamine (Sigma-Aldrich), 100 U/ml penicillin, and 10 g/ml 
streptomycin (Sigma-Aldrich) in a 37°C humidified atmosphere supplemented with 5% CO2. 
Where indicated, the cells were treated with 100 ng/ml recombinant human GDF5 (rhGDF5, 
Biopharm GmbH) or 10 µM retinoic acid (RA, Sigma-Aldrich). 
 
Reverse-transcriptase polymerase chain reaction (RT-PCR) 
 
For RT-PCR, total RNA was extracted from SH-SY5Y. RNA was extracted using the method 
described by Berk and Sharp (Berk and Sharp 1977). RNA samples were treated with RQ1 
DNAse (Promega) for 20 min at room temperature before being neutralised. Complementary 
DNA (cDNA) synthesis was performed using 1 µg RNA following the ImProm-II™ kit 
protocol (Promega Inc.). Negative controls where the reverse transcriptase was left out of the 
reaction were also prepared (RT-). PCR was performed using the primers and conditions 
indicated in Table 1. Aliquots of the reactions were electrophoresed on 1.5% agarose gels and 
photographed.  
 
Immunocytochemistry 
 
10,000 SH-SY5Y cells were seeded in 24-well plates and grown for 7 days in the presence of 
GDF5 (100 ng/ml). Control cultures were left untreated. Cells were fixed in 4% 
paraformaldehyde or ice-cold methanol for 15 min followed by permeabilization in 0.2% 
Triton-X. Immunodetection was performed using the following antibodies: mouse 
monoclonal antibodies to BMPR1A (1:500, R&D Systems), BMPR1B (1:000, R&D 
Systems), BMPR2 (1:1000, R&D Systems), ROR2 (1:500, R&D Systems), TH (1:500, 
NovoCastra Laboratories), and rabbit polyclonal antibodies to DAT1 (1:500, Santa Cruz 
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biotechnology), SMAD 1/5/8 (1:1000, Santa Cruz biotechnology) and phospho-SMAD 1/5 
(1:1000, Cell Signaling Technology). Alexa 488-conjugated donkey anti-rabbit and Alexa 
594-conjugated donkey anti-mouse secondary antibodies (1:1500, Molecular Probes) were 
used. Cells were counterstained with DAPI. The cells were imaged on an Olympus IX70 
inverted microscope. The fluorescence intensity of individual cells stained for phospho-
SMAD 1/5/8 was measured using the Image J analysis software (Rasband, WJ, 
http://rsb.info.nih.gov/ij/). The relative fluorescence intensity was calculated as the intensity 
of individual cells after substraction of the background noise. Results were compared using a 
Student’s t-test. 
 
Immunoblotting 
 
Total protein extracts were prepared by homogenizing cells in protein extraction buffer (70 
mM TRIS-HCl pH 6.8, 10% glycerol, 3% SDS and 700 mM 2-mercaptoethanol) followed by 
centrifugation at 14000g. 20 μg were electrophoresed on 10% SDS-polyacrylamide gels and 
were transblotted to nitrocellulose membranes. Immunodetection was performed using rabbit 
polyclonal antibodies to SMAD 1/5/8 (1:2000, Santa Cruz biotechnology) and phospho-
SMAD 1/5/8 (1:2000, Cell Signaling Technology) or rabbit polyclonal anti-actin (1:10000, 
Santa Cruz Biotechnology) antibodies. Results were visualized by chemiluminescence. 
 
Cell growth assay 
 
50,000 SH-SY5Y cells were seeded in 6-well plates. Cells were collected 2, 4 and 7 days 
after seeding, stained with trypan blue and counted using a haemacytometer. Growth curves 
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were plotted and differences were assessed by performing a one-way ANOVA followed by a 
Dunnett’s post-hoc test. 
 
Measurement of cellular morphology 
 
10 to 15 microscopic fields were randomly selected from three independent experiments, 
photographed using an Olympus IX70 inverted microscope and all cells in each photograph 
were measured. Neurite branching was assessed by counting the numbers of “nodes” per cell. 
Primary nodes were considered branches from the cell body, and secondary nodes were 
considered branches of primary neurites. The length of the neuritic arborisation was 
estimated using standard stereological procedures (Mayhew 1992). A line grid was 
superimposed on the microscopic images and the number of times a neurite intersects the grid 
was recorded. The neurite length was calculated using the following formula;  
 NL = a x T x /2 
Where a = the number of times the neurite intersect the grid lines, T = the distance between 
the gridlines on the magnified image (taking into account the magnification factor). Results 
were compared using a Student’s t-test. 
 
Neuroprotection assays 
 
100 000 cells per well were seeded in 24-well plates and grown in the presence or absence of 
rhGDF5 (100 ng/ml). After 24h, half of the wells were treated for 1h with 50 µM 6-OHDA. 
The cells were then rinsed three times in saline solution and fed either with culture medium 
or culture medium supplemented with 100 ng/ml rhGDF5 for an additional 24h. This 
treatment modality produced six experimental groups (Figure 4A). Following the second 
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incubation, an MTT assay was performed to assess cell viability. Thiazolyl Blue Tetrazolium 
Bromide (MTT) was added to cells at a concentration of 0.5 mg/ml in the culture medium 
and incubated for 3h. Cell culture medium was removed and the cells were lysed using a 
mixture of Isopropanol:HCl (24:1). Absorbance was measured at 540 nm with a reference 
wavelength of 690 nm. The mean of 9 independent samples were calculated for each group 
and results were compared using an ANOVA followed by Tukey’s post-hoc analysis.  
 
Results 
 
GDF5 signalling machinery is expressed in SH-SY5Y cells 
 
To assess their suitability as a neuronal model to further study the neurotrophic properties and 
downstream signalling pathways of GDF5, human neuroblastoma SH-SY5Y cells were tested 
for the expression of the various GDF5 receptors, BMPR1a, BMPR1b, BMPR2 and ROR2. 
RT-PCR experiments revealed that the mRNA for each of the four receptors is expressed in 
SH-SY5Y cells (Figure 1A). Immunocytochemistry confirmed that all four receptors are 
expressed on the surface of SH-SY5Y cells; although cell surface expression of BMPR1a was 
low compared to the other receptors (Figure 1B). Results also showed that the intracellular 
machinery for signal processing, SMAD proteins 1, 5, and 8, is present in both 
unphosphorylated (inactive) and phosphorylated (active) forms (Figure 2A). Controls 
performed for each secondary antibody confirmed the specificity of the staining (data not 
shown).  
 
Given that the cells express the receptors and downstream transcription factors necessary for 
GDF-5 signalling, we next assessed whether GDF5 induced a physiological effect in SH-
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SY5Y cells, by quantifying the relative intensity of phosphorylated SMAD 1, 5, 8 present in 
the nucleus. Results showed that treatment with 100 ng/ml GDF5 for 7 days resulted in a 
significant (35%) increase in phospho-SMAD 1/5 signal intensity compared to untreated cells 
(p<0.001, Figure 2A and Figure 2B). An immunoblot confirmed these findings. Protein 
extracts from GDF5-treated and untreated SH-SY5Y cells were probed with antibodies 
against SMAD 1/5/8 or their phosphorylated form. Comparison to an actin control revealed 
that an increase in phosphorylated SMAD proteins in the GDF5-treated sample (Figure 2C). 
These data suggest that GDF5 should be able to actively induce changes in gene expression 
as a result of nuclear accumulation of phospho-SMAD proteins, and this may induce 
phenotypic changes in the cells. 
 
GDF5 inhibits the growth of SH-SY5Y cells 
 
To assess any potential phenotypic changes, we examined the growth and differentiation of 
the SH-SY5Y cells. Firstly we examined the growth rates of these cells in response to retinoic 
acid and GDF5. To assess the capacity of GDF5 to induce post-mitotic growth arrest of SH-
SY5Y cells, growth rates were measured over a period of 7 days in the presence of 100 ng/ml 
GDF5. We used cells grown in 10 µM RA as a positive control, as RA has been shown to 
induce the post-mitotic neuronal differentiation of SH-SY5Y cells and inhibit their growth 
rates (Pahlman et al. 1995; Pahlman et al. 1984). As expected, RA strongly inhibited the 
growth of SH-SY5Y cells after 4 and 7 days of treatment (p<0.001, Figure 3). Interestingly, 
our results show that treatment with GDF5 also resulted in growth inhibition (Figure 3). 
While the difference is not as strong as the one elicited by RA, it is nonetheless significant 
compared to the control after 4 days and remains significant at 7 days (p< 0.05, Figure 3).   
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GDF5 stimulates neuronal differentiation of SH-SY5Y 
 
While the results above may be an effect of GDF5 on cellular differentiation, they could also 
be a consequence of mitotic inhibition without differentiation. One of the morphological 
features of maturing neurones is the development of a neuritic arborisation and GDF5 has 
been shown to promote neurite outgrowth in primary VM cultures (O'Keeffe et al. 2004a). To 
assess the effect of GDF5 on neuronal differentiation, we analysed the number of primary 
and secondary neurites on GDF5-treated, RA-treated and untreated SH-SY5Y cells (Figure 
4A). Our results show that after 7 days of treatment, 100 ng/ml GDF5 induced an increase in 
the number of neurites compared to untreated controls (Figure 4B). While the difference 
remained close to significance levels for the number of primary neurites (p=0.067), it reached 
statistical significance for second order neurites (p<0.05, Figure 4B). The control retinoic 
acid-treated cells showed a significant increase in the number of primary neurites (p<0.05) 
while there was a non-significant increase in the number of secondary neurites (figure 4B). 
Furthermore, GDF5-treated cells showed a 27% increase in total neurite length compared to 
control cells (p<0.05, Figure 4C) while the RA-treated cells showed a 42% increase in total 
neurite length (p<0.001). Altogether, these results suggest that GDF5 induces differentiation 
rather than simply inducing growth arrest. 
 
Treatment with GDF5 does not affect tyrosine hydroxylase expression 
 
Previous results from our lab showed that treatment of primary VM cultures with GDF5 leads 
to an increased survival/number of DA neurones (O'Keeffe et al. 2004a). SH-SY5Y cells 
have been reported by some groups to readily express tyrosine hydroxylase (TH, the rate-
limiting enzyme in the synthesis of DA) (Gomez-Santos et al. 2002; McMillan et al. 2007), 
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while others failed to demonstrate expression (Mastroeni et al. 2008). To assess whether the 
neuroblastoma cell line model used here could recapitulate the results obtained using primary 
cultures, we analysed TH expression by RT-PCR, immuncytochemistry and immunoblotting 
in cultures maintained in the presence of 100 ng/ml GDF5 for 4 to 7 days. Using adult rat 
midbrain extracts or cryosections as positive controls, we were unable to demonstrate the 
presence of TH expression in SH-SY5Y cells in the presence or absence of GDF5 (data not 
shown).  
 
Treatment with GDF5 protects SH-SY5Y cells from 6-OHDA induced toxicity 
 
Having shown that GDF5 stimulates neuronal maturation we next investigated its 
neuroprotective properties. GDF5 has been previously shown to protect DA neurones from 6-
OHDA-induced neurotoxicity both in vitro and in vivo (O'Keeffe et al. 2004a; Sullivan et al. 
1997; Sullivan et al. 1999; Sullivan et al. 1998). To assess whether SH-SY5Y cells could 
represent a good cellular model to study the neuroprotective properties of GDF5, we 
demonstrated that SH-SY5Y cells express the dopamine transporter (DAT) involved in the 
uptake of 6-OHDA, on their surface (data not shown). Various treatment modalities with 
GDF5 and 6-OHDA were devised (Figure 5A) and neuronal survival was assessed using 
MTT assays. 
 
Cell viability was decreased by 34% following a 6-OHDA treatment (50 µM, 1h) compared 
to untreated controls (group 2 vs. group 1, p< 0.01, Figure 5B). Continuous GDF5 treatment 
significantly protected cells from 6-OHDA-induced toxicity (group 3 vs. group 2, p<0.05, 
figure 5B). There was no observable difference between groups 1 and 3 (100% vs. 98% 
viability). GDF5 treatment applied only before or only after the 6-OHDA insult (groups 4 and 
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5 respectively) conferred significant neuroprotection (group 4 vs. group 2 p<0.05 and group 5 
vs. group 2, p<0.05, Figure 4B). With the exception of group 2, there was no difference in 
viability between group 1 and any of the other groups (Figure 5). 
 
Discussion 
The neuroprotective properties of GDF5 have been well documented in primary neuronal 
cultures and in in vivo models of Parkinson’s disease. However, due to the mixed cell 
populations of these models, it is not possible to determine whether the effects are direct or if 
they are mediated through other cell types, such as glial cells. In an attempt to establish a cell 
line model to further study the neuroprotective effects of GDF5, we have characterised the 
neuroblastoma cell line SH-SY5Y with regards to the expression of GDF5 surface receptors 
and its responsiveness to this neurotrophin. 
 
This study confirmed that all four types of GDF5 receptor are expressed on SH-SY5Y cells. 
In addition, we showed that the principal signal transduction machinery for GDF5, SMAD 
proteins 1, 5 and 8, are present in SH-SY5Y cells and is activated in response to GDF5 
treatment. This neuroblastoma cell line has previously been shown to respond to neuronal 
differentiating agents by exiting the mitotic cycle and acquiring a more complex dendritic 
arborisation (Pahlman et al. 1995; Pahlman et al. 1984). Our results showed that, while the 
effect of GDF5 is not as strong as that of RA, cell growth was nonetheless significantly 
inhibited when the cells were grown in the presence of GDF5. Analysis of the dendritic 
arborisation revealed that treatment with GDF5 for 7 days resulted in the development of a 
more extensive neurite network, particularly at secondary branching points.  
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Some authors have previously reported that TH is readily expressed by SH-SY5Y cells, while 
others reported that TH is not expressed in undifferentiated SH-SY5Y cells (Gomez-Santos et 
al. 2002; Mastroeni et al. 2008; McMillan et al. 2007). In addition, GDF5 has previously been 
reported to induce DA differentiation of rat primary VM cultures (O'Keeffe et al. 2004a). The 
absence of TH induction following GDF5 application found in the present paper could be due 
to a variety of factors, including clonal variations, defects in signaling pathways or in the TH 
gene promoter or to the dosage of GDF5 used. Gomez-Santos and collaborators (2002) 
previously showed that in SH-SY5Y cells, TH expression is induced through the activation of 
SMAD2/3 and not SMAD1/5/8. The latter group of SMADs are the targets of the BMPR 
pathway (ten Dijke et al. 2000) suggesting that the induction of the dopaminergic phenotype 
in primary VM cultures may have been an indirect effect of GDF5 treatment. This is further 
supported by results from Castelo-Branco et al. showing that secretion of Wnt5a by VM glia 
is an important event in the differentiation of VM dopaminergic neurones and that blockade 
of this signal results in reduced DA differentiation (Castelo-Branco et al. 2006). Interestingly, 
Wnt5a is a ligand for ROR2 and induces homodimerization of the receptor on the cell surface 
(Liu et al. 2008). While it is obvious that the SH-SY5Y cells do not recapitulate the events 
observed in GDF5-induced primary VM dopaminergic differentiation, we propose that the 
stimulation of TH expression observed in the O’Keeffe study was ultimately achieved via 
signals secreted from surrounding cells in primary cultures. For example, Wnt5a secreted by 
glial cells could have acted on the neurones but ultimately, GDF5 stimulation did not directly 
influence neuronal dopaminergic differentitation. 
 
In our final series of experiments, we demonstrated that, while SH-SY5Y cells do not 
reproduce all the dopaminergic features of primary VM cultures, they nonetheless represent 
an excellent model to study the neuroprotective effects of GDF5. We confirmed that the SH-
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SY5Y cells express the dopamine transporter protein DAT. Although some authors have 
shown that 6-OHDA neurotoxicity requires neuronal uptake by DAT in vivo (Glinka et al. 
1997; Storch et al. 2004), results obtained from primary cell cultures and cell lines, including 
SH-SY5Y, suggest that 6-OHDA neurotoxicity in vitro may be mediated independently of 
DAT (Abad et al. 1995; Michel and Hefti 1990; Rosenberg 1988; Storch et al. 2000). 
Notwithstanding the mechanism, SH-SY5Y cells remain susceptible to the neurotoxic effects 
of 6-OHDA (Lopes et al. 2010; Storch et al. 2000). Our results showed that continuous 
treatment with GDF5 (group 3) could prevent neurotoxicity induced by 6-OHDA. Cells 
treated with GDF5 prior to a 6-OHDA pulse resisted its toxic effects (group 4, 
neuroprotection) but most importantly, application of GDF5 after the 6-OHDA pulse rescued 
most of the cells from the neurotoxic insult (group 5, neurorescue). Considering that 
neuroprotection following the onset of the disease is one of the major therapeutic avenues for 
the treatment of PD, our results suggest that GDF5 has enormous potential and the 
establishment of the model described here will greatly facilitate the elucidation of the 
pathways and intracellular machinery by which it confers neuroprotection.  
 
GDF5 is one of the most potent neurotrophins characterised to date in animal models of PD 
but its molecular characterisation has been hindered by the lack of a good cellular model. 
While it remains an imperfect model for the characterisation of dopaminergic effects, our 
results show that SH-SY5Y cells are well suited to study some of the molecular events 
associated with GDF5 signalling and its role in neuronal differentiation and neuroprotection. 
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Table 1: Gene-specific primers and PCR conditions. 
Target 
gene 
Primer  Sequence (5’- 3’) MgCl2 
concentration 
(mM) 
Annealing 
Temperature 
(°C) 
Product 
Size 
(bp) 
BMPR1A 
Forward CGAAAAAGTGGCGGTGAAAGTATT 
1.5 57 543 
Reverse ATTAGGCCGAAGCTGTAGATGTCA 
BMPR1B 
Forward AAAGTGGCGTGGCGAAAAGGTAGC 1.5 
 
57 406 
Reverse TTTAACAGCCAGGCCCAGGTCAGC 
BMPR2 
Forward GCTTCGCAGAATCAAGAACG 1.5 
 57 349 Reverse GTGGACTGAGTGGTGTTGTG 
ROR2 
Forward ATCGCCCGCTCCAACCCtCTCATC 
1.0 62 404 
Reverse ATCCCCATCTTGCTGCcGTCTCG 
TH 
Forward GGCCGCCCTGCTCAGTGGTGTG 1.5 
 62 430 Reverse GGCCGCCCTGCTCAGTGGTGTG 
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FIGURE LEGENDS 
 
Figure 1: Expression of GDF5 receptors in SH-SY5Y cells. A) Representative gel 
electrophoresis of PCR products for BMPR1a, BMPR1b, BMPR2 and ROR2. MW: 
Molecular weight marker, +: RT-positive reaction, -: RT-negative control. B) Representative 
images showing immunocytochemical staining for the cell surface receptors for GDF5 
(BMPR1a, BMPR1b, BMPR2, ROR2) as well as a negative control in which the primary 
antibody was omitted. The cells were counterstained with DAPI. Phase contrast images were 
also taken at 60X magnification (scale bar = 10 µm). 
 
Figure 2: Expression of SMAD proteins in SH-SY5Y cells. A) Representative images 
showing immunocytochemical staining for SMAD 1/5/8 and phosphorylated-SMAD 1/5/8 
proteins in untreated SH-SY5Y and GDF5-treated (100 ng/ml for 7 days) cells. Images were 
taken at 20X magnification (scale bar = 50 µm). B) The relative immunofluorescence 
intensity of untreated and GDF5-treated cells expressing phospho-SMAD 1/5/8. Data are 
presented as the mean relative fluorescence intensity ± S.E.M. (*** p<0.001 vs. untreated 
cells, Student’s t-test, n=120 cells for each group). C) Western blot showing the effects of 
GDF5 treatment on SMAD proteins phosphorylation.  
 
Figure 3: Growth rates of untreated (circles), GDF5-treated (100 ng/ml, squares) and RA-
treated SH-SY5Y cells (10 µM, triangles). Data are presented as the mean ± S.E.M of 8 
independent samples (* p<0.05 and *** p<0.001 compared to untreated cells; one-way 
ANOVA with Dunnett’s post-hoc test).  
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Figure 4: GDF5 induces morphological changes in SH-SY5Y cells. A) Phase contrast 
microphotographs of untreated, GDF5-treated (100 ng/ml), and RA-treated (10 µM) SH-
SY5Y cells. B) The numbers of primary and secondary neurites in untreated, GDF5-treated 
(100 ng/ml), and RA-treated (10 µM) cells after 7 days. Data are presented as the mean ± 
S.E.M. of 60 cells from 3 experiments (* p<0.05 compared to untreated cells, One way 
ANOVA with Dunnett’s post-hoc analysis). C) The length of the neuritic arborisations in 
untreated, GDF5-treated (100 ng/ml), and RA-treated (10 µM) cells after 7 days. Data are 
presented as the mean ± S.E.M. length per cell of 60 cells from 3 experiments (* p<0.05 and 
*** p<0.001 compared to untreated cells, one-way ANOVA with Dunnett’s post-hoc 
analysis). 
 
Figure 5: Neuroprotective effects of GDF5 on SH-SY5Y cells. A) Experimental groups 
assessed. B) Cell viability in each treatment group after 48h, as measured by MTT assays. 
Mean absorbance values ± S.E.M. are presented, with untreated SH-SY5Y cells (group 1) 
considered as 100% viability (* p<0.05 compared to group 1, $ p<0.05 compared to group 2, 
ANOVA with post-hoc Tukey’s test). 
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